TPOXX

USDailyMed:Tecovirimat J05AX24(WHO) CA:℞-onlyUS:℞-onlyEU:Rx-only N-{3,5-Dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl}-4-(trifluoromethyl)benzamide 869572-92-9 16124688 DB12020 17281586Y F925RR824R D09390Yas monohydrate:D11557Y ChEMBL1257073Y Interactive image FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)C2C(C3C=CC2C2CC32)C1=O InChI=1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)YKey:CSKDFZIMJXRJGH-UHFFFAOYSA-NY Tecovirimat, sold under the brand nameTpoxxamong others,is anantiviral medicationwith activity againstorthopoxvirusessuch assmallpoxandmpox.In 2018 it was the first antipoxviral drug approved in the United States. The drug works by blocking cellular transmission of orthopoxviruses, thus preventing disease. Tecovirimat has been effective in laboratory testing; it has been shown to protect animals frommpoxandrabbitpoxand causes no serious side effects in humans.Tecovirimat was first used for treatment in December 2018, after a laboratory-acquiredvacciniavirus infection. As of 2014 two million doses of tecovirimat were stockpiled in the USStrategic National Stockpileshould an orthopoxvirus-basedbioterror attackoccur.The U.S.Food and Drug Administration(FDA) considers it to be afirst-in-class medication.